Drug Profile

PDL1 targeted antisense oligonucleotide therapeutic - Secarna Pharmaceuticals

Alternative Names: PDL1 antisense oligonucleotide - Secarna Pharmaceuticals

Latest Information Update: 28 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Secarna Pharmaceuticals
Class Antineoplastics; Antisense oligonucleotides
Mechanism of Action Gene silencing; Programmed cell death-1 ligand-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Mar 2025 No recent reports of development identified for preclinical development in Cancer in Germany
20 Dec 2023 Pharmacodynamics data from a preclinical trial in Cancer released by Secarna Pharmaceuticals (Secarna Pharmaceuticals pipeline, December 2023)
31 Mar 2023 Preclinical development is ongoing Germany (Secarna Pharmaceuticals pipeline, March 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com